Zhengda Tianqing capsule of androtinib hydrochloride was approved as the third indication - the third line treatment of small cell lung cancer.

On September 4, China biopharmaceutical announced that its subsidiary company, Zhengda Tianqing Pharmaceutical Group Co., Ltd., independently developed the anti-tumor drug "androtinib hydrochloride capsule" (trade name: fukewei), which was approved by the State Food and Drug Administration for drug registration approval and new indications "three line treatment of small cell lung cancer" This is the third indication of the capsule after it was approved last year for the treatment of advanced non-small cell lung cancer and in June this year for the treatment of soft tissue sarcoma The announcement shows that for the clinical treatment of small cell lung cancer, the current standard first-line treatment is etoposide / platinum combination chemotherapy, and the efficacy has been stagnant for more than 20 years; the second-line treatment is topotecan chemotherapy, and the effect is not ideal Small cell lung cancer urgently needs new drugs Enrotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which has the effect of anti-tumor angiogenesis and tumor growth inhibition The efficacy of three-line treatment of small cell lung cancer has been clinically confirmed The clinical efficacy analysis showed that compared with the placebo group, the disease-free progression survival period of patients with small cell lung cancer treated with enrotinib hydrochloride was significantly prolonged China's biopharmaceutical industry has been actively responding to the call of the state to reduce the drug burden of domestic cancer patients The price of focovide is only 50% - 60% of the same kind of imported drugs, and it has the characteristics of small dosage and convenient use of drugs Since its launch last year, focovir has provided numerous cancer patients with pain relief, life delay, and quality of life improvement, as well as more drug choices for clinicians, with positive social significance and broad market prospects.